Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29795663 | 0.78 | ASAH1 (0.97) | ASAH1NPC1ALDH1A1 | |
| SCHEMBL3048347 | 0.78 | KMT2A (0.47) | ASAH1MAPK1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL26346015 | 0.77 | KDM4E (0.75) | SMN1; SMN2LMNAL3MBTL1KDM4ENPC1 | |
| SCHEMBL17309687 | 0.76 | KDM4E (1.00) | SMN1; SMN2LMNAL3MBTL1KDM4ENPC1 | |
| SCHEMBL595111 | 0.75 | TDP1 (0.68) | SMN1; SMN2LMNAL3MBTL1NPC1HTT | |
| SCHEMBL11408718 | 0.75 | TDP1 (0.68) | SMN1; SMN2LMNAL3MBTL1NPC1HTT | |
| SCHEMBL4888041 | 0.75 | TDP1 (0.68) | SMN1; SMN2LMNAL3MBTL1NPC1HTT | |
| SCHEMBL9038701 | 0.75 | TDP1 (0.68) | SMN1; SMN2LMNAL3MBTL1NPC1HTT | |
| SCHEMBL16097150 | 0.75 | TDP1 (0.68) | SMN1; SMN2LMNAL3MBTL1NPC1HTT | |
| SCHEMBL9038339 | 0.75 | TDP1 (0.68) | SMN1; SMN2LMNAL3MBTL1NPC1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | claimed |
| EP-1626964-B1 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | claimed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | claimed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | claimed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | claimed |
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | disclosed |
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1626964-B1 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287377-A1 | New benzimidazole derivatives | CYP2C9, CDK9, CCNI | ASAH1 4165/4885MAPK1 3431/4885SMN1; SMN2 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.